GHENT, Belgium, 6 August, 2007 - Ablynx, the biopharmaceutical company engaged in the discovery and development of Nanobodies®, today announced that it has appointed Dr Josefin-Beate (Josi) Holz, as its first Chief Medical Officer.
GHENT, Belgium, 6 August, 2007 - Ablynx, the biopharmaceutical company engaged in the discovery and development of Nanobodies®, today announced that it has appointed Dr Josefin-Beate (Josi) Holz, as its first Chief Medical Officer.
